Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
Open Access
- 1 October 2023
- journal article
- case report
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2879-2883
Abstract
Secukinumab, a monoclonal antibody targeting interleukin-17 (IL-17), has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide. Here we report a 35-year-old female patient with PPP who developed AA after completing the induction period of secukinumab treatment. Discontinuing secukinumab and initiating treatment with tofacitinib resulted in a significant improvement in both PPP and AA. The emergence of AA in this patient can be attributed to paradoxical skin reactions associated with IL-17 inhibitors. Tofacitinib appears to alleviate biologic-induced AA during PPP syndrome treatment.Keywords
This publication has 16 references indexed in Scilit:
- Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis SyndromeJAMA Dermatology, 2021
- Development of alopecia in patients treated with interleukin‐17 inhibitorsDermatologic Therapy, 2020
- Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in JapanThe Journal of Dermatology, 2020
- Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging TreatmentsAmerican Journal of Clinical Dermatology, 2020
- Palmoplantar pustulosis: Current understanding of disease definition and pathomechanismJournal of Dermatological Science, 2020
- Alopecia areata y pustulosis palmoplantar: informe de 4 casosActas Dermo-Sifiliograficas, 2018
- IL-17 inhibition: is it the long-awaited savior for alopecia areata?Archives of Dermatological Research, 2018
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areataJCI Insight, 2016
- Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective studyJournal of the American Academy of Dermatology, 2014
- Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agentsJournal of the European Academy of Dermatology and Venereology, 2011